At Peter Mac there are many specialised groups actively engaged in clinical research. Our aim is to improve treatment, and care and experience outcomes of cancer patients and their support networks.
Survivorship research encompasses any research that improves survival or outcomes for people affected by cancer.
Allied health professionals are a large professional group in health across Victoria and a core component of the multidisciplinary treating teams.
Developing innovative and effective healthcare interventions and resources for people affected by cancer.
Improving clinical science and better surgical, anaesthesia and interventional pain medicine outcomes for cancer patients.
Working with families to investigate hereditary cancer syndromes and better manage their cancer risk.
Developing and improving cancer imaging and diagnostic technologies for cancer patients.
The National Centre for Infections in Cancer (NCIC) is an integrated health care program for reducing infections in cancer. Find information on guidelines, toolkits, surveillance, latest publications and events
Our multidisciplinary research group is committed to improving our understanding and knowledge of the health outcomes of young people living with cancer.
Research dedicated to providing safe and effective medicines for cancer patients
Optimising physical sciences for the delivery of cancer radiotherapy treatments that increase tumour exposure to effective therapy and simultaneously reduce exposure to normal tissue.
Radiation Oncology at Peter Mac is the largest and most academically active radiotherapy treatment centre in Australia. Our research aims to provide the most up-to date and effective evidence-based treatment for patients who require radiotherapy.
Radiation Oncology at Peter Mac is the largest and most academically active radiotherapy treatment centre in Australia. Radiation Therapists play an integral role in the undertaking of many of these multidisciplinary academic pursuits.
Employing clinical trials of ‘epigenetic drugs’ for patients with blood cancers incorporating detailed laboratory studies on how these new drugs work and how to use them better.
